In Part 2 of our discussion on the FDA’s new guidance for clinical trials, we move from theory to practice. Ted B. from Medvector joins us again to dive into solutions for addressing potential challenges when implementing this new flexibility allowing healthcare providers (HCPs) to conduct visits with Principal Investigator (PI) oversight.

In Part 2 of our discussion on the FDA’s new guidance for clinical trials, we move from theory to practice. Ted B. from Medvector joins us again to dive into solutions for addressing potential challenges when implementing this new flexibility allowing healthcare providers (HCPs) to conduct visits with Principal Investigator (PI) oversight.

&nbsp;In Part 2 of our discussion on the FDA’s new guidance for clinical trials, we move from theory to practice. Ted B. from Medvector joins us again to dive into solutions for addressing potential challenges when implementing this new flexibility allowing healthcare providers (HCPs) to conduct visits with Principal Investigator (PI) oversight.&nbsp;

FDA Decentralized Guidance with Ted Barduson PART 2

The good, the bad, the dirty of the Science, Technology, Engineering and Math world.&nbsp; New Episodes Weekly!

Science

Technology

Education

The good, the bad, the dirty of the Science, Technology, Engineering and Math world.  New Episodes Weekly!

Share FDA Decentralized Guidance with Ted Barduson PART 2

Sign up to save your podcasts

FDA Decentralized Guidance with Ted Barduson PART 2

FDA Decentralized Guidance with Ted Barduson PART 2